DK1463563T3 - Superoxiddismutas-mimetika til behandling af öjenlidelser og -sygdomme - Google Patents

Superoxiddismutas-mimetika til behandling af öjenlidelser og -sygdomme

Info

Publication number
DK1463563T3
DK1463563T3 DK02786915T DK02786915T DK1463563T3 DK 1463563 T3 DK1463563 T3 DK 1463563T3 DK 02786915 T DK02786915 T DK 02786915T DK 02786915 T DK02786915 T DK 02786915T DK 1463563 T3 DK1463563 T3 DK 1463563T3
Authority
DK
Denmark
Prior art keywords
treatment
dismutas
mimetics
diseases
eye disorders
Prior art date
Application number
DK02786915T
Other languages
Danish (da)
English (en)
Inventor
Robert J Collier Jr
Mark R Hellberg
Peter G Klimko
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of DK1463563T3 publication Critical patent/DK1463563T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK02786915T 2001-12-14 2002-12-06 Superoxiddismutas-mimetika til behandling af öjenlidelser og -sygdomme DK1463563T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34038901P 2001-12-14 2001-12-14
PCT/US2002/039037 WO2003051458A1 (en) 2001-12-14 2002-12-06 Superoxide dismutase mimics for the treatment of ocular disorders and diseases

Publications (1)

Publication Number Publication Date
DK1463563T3 true DK1463563T3 (da) 2009-04-20

Family

ID=23333158

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02786915T DK1463563T3 (da) 2001-12-14 2002-12-06 Superoxiddismutas-mimetika til behandling af öjenlidelser og -sygdomme

Country Status (19)

Country Link
US (2) US7759333B2 (pl)
EP (1) EP1463563B1 (pl)
JP (1) JP2005513063A (pl)
KR (1) KR100951606B1 (pl)
CN (2) CN101092432A (pl)
AT (1) ATE422944T1 (pl)
BR (1) BR0214957A (pl)
CA (1) CA2470721C (pl)
CY (1) CY1108983T1 (pl)
DE (1) DE60231246D1 (pl)
DK (1) DK1463563T3 (pl)
ES (1) ES2319399T3 (pl)
HK (1) HK1069785A1 (pl)
MX (1) MXPA04005601A (pl)
PL (1) PL210225B1 (pl)
PT (1) PT1463563E (pl)
SI (1) SI1463563T1 (pl)
WO (1) WO2003051458A1 (pl)
ZA (1) ZA200404435B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101092432A (zh) * 2001-12-14 2007-12-26 艾尔科公司 治疗眼睛障碍和疾病的超氧化物歧化酶模拟物
AU2004305531B2 (en) * 2003-12-11 2009-11-26 Alcon, Inc. Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
JP5683484B2 (ja) 2008-12-19 2015-03-11 ジェネンテック, インコーポレイテッド 化合物と使用法
PL2433640T3 (pl) 2010-09-24 2020-06-01 Omnivision Gmbh Kompozycja zawierająca SOD, luteinę i zeaksantynę
KR101214364B1 (ko) * 2011-02-15 2012-12-21 한림대학교 산학협력단 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물
US9149483B2 (en) * 2011-09-26 2015-10-06 Galera Labs, Llc Methods for treatment of diseases
WO2023120828A1 (ko) * 2021-12-23 2023-06-29 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 건성 황반변성의 예방 또는 치료용 용도
WO2023224136A1 (ko) * 2022-05-16 2023-11-23 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 당뇨망막병증 또는 포도막염의 예방 또는 치료용 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5209926A (en) * 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
SE9402816D0 (sv) 1994-08-24 1994-08-24 Pharmacia Ab Method and meams for drug administration
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
CA2309154C (en) * 1997-11-03 2010-02-16 Duke University Substituted porphyrins
AU5251999A (en) 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
WO2000023568A2 (en) 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
DE60018925T2 (de) 1999-05-27 2006-04-13 Pharmacia Corp.(N.D.Ges.D.Staates Delaware) Biomaterialien, modifiziert mit superoxid-dismutase imitatoren
CN101092432A (zh) 2001-12-14 2007-12-26 艾尔科公司 治疗眼睛障碍和疾病的超氧化物歧化酶模拟物

Also Published As

Publication number Publication date
PT1463563E (pt) 2009-03-19
CA2470721C (en) 2011-07-12
ZA200404435B (en) 2006-05-31
WO2003051458A1 (en) 2003-06-26
BR0214957A (pt) 2004-12-14
HK1069785A1 (en) 2005-06-03
SI1463563T1 (sl) 2009-06-30
CA2470721A1 (en) 2003-06-26
DE60231246D1 (de) 2009-04-02
MXPA04005601A (es) 2004-12-06
ES2319399T3 (es) 2009-05-07
US8003635B2 (en) 2011-08-23
PL369607A1 (pl) 2005-05-02
ATE422944T1 (de) 2009-03-15
CY1108983T1 (el) 2014-07-02
EP1463563A1 (en) 2004-10-06
CN101092432A (zh) 2007-12-26
EP1463563B1 (en) 2009-02-18
AU2002351267A1 (en) 2003-06-30
KR20040063943A (ko) 2004-07-14
KR100951606B1 (ko) 2010-04-09
CN1620325A (zh) 2005-05-25
JP2005513063A (ja) 2005-05-12
US7759333B2 (en) 2010-07-20
AU2002351267B2 (en) 2007-04-05
US20050032768A1 (en) 2005-02-10
US20100204194A1 (en) 2010-08-12
PL210225B1 (pl) 2011-12-30

Similar Documents

Publication Publication Date Title
CY1108983T1 (el) Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων
WO2002085248A3 (en) Prostanoids augment ocular drug penetration
DE60101265D1 (de) Behandlung von augenschmerzen
EA200400518A1 (ru) Способы лечения глазных неоваскулярных заболеваний
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
BR0317026A (pt) Mìmicos de superóxido dismutase para o tratamento de distúrbios e doenças oculares
DK1263504T3 (da) Anvendelse af forbindelser med 5-HT1A aktivitet, som er anvendelige til behandling af lidelser i den ydre retina
EA200300560A1 (ru) Улучшенный способ лечения
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
ATE487482T1 (de) Superoxid-dismutase-mimika zur behandlungvon augenstörungen und erkrankungen
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
PT1178819E (pt) Glutationa-redutase para a terapia e profilaxia da sida
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
ATE344054T1 (de) Behandlung von okularen neovaskularen erkrankungen
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
BRPI0417549A (pt) miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal